脓毒症中DA1.a细胞的人白细胞介素/白血病抑制因子血浆水平升高与休克及不良预后相关。

Increased plasma levels of human interleukin for DA1.a cells/leukemia inhibitory factor in sepsis correlate with shock and poor prognosis.

作者信息

Villers D, Dao T, Nguyen J M, Bironneau E, Godard A, Moreau M, De Groote D, Nicolas F, Soulillou J P, Anegon I

机构信息

Service de Réanimation Médicale, Laboratoire de Statistiques et d'Informatique Médicale (CHU Hôtel-Dieu), Institut National de la Santé et de la Recherche Médicale (U211), Nantes, France.

出版信息

J Infect Dis. 1995 Jan;171(1):232-6. doi: 10.1093/infdis/171.1.232.

DOI:10.1093/infdis/171.1.232

PMID:7798671

Abstract

Animal study results have suggested a role in sepsis for human interleukin for DA1.a cells/leukemia inhibitory factor (HILDA/LIF). HILDA/LIF and interleukin-6 (IL-6) levels were prospectively studied by serial ELISAs in 34 septic patients. HILDA/LIF was detected in 11 of 34 patients at plasma levels of 100-37,000 pg/mL. Peak HILDA/LIF levels correlated with increased temperature and creatinine and IL-6 and with decreased arterial CO2 (P < .05). Multivariate analysis showed that shock and decreased arterial CO2 accounted for 75% of peak HILDA/LIF plasma variations (R2 = .753). Fatal outcome was most often associated with detectable HILDA/LIF (> 56 pg/mL) and peak IL-6 plasma levels > 850 pg/mL (sensitivity, 83%; specificity, 87%), but both (at respective levels of > 480 and > 850 pg/mL) were associated with fatal outcome. HILDA/LIF was detected in septic patients exhibiting shock, and its levels correlated with higher mortality and shorter survival.

摘要

动物研究结果表明，人DA1.a细胞白细胞介素/白血病抑制因子（HILDA/LIF）在脓毒症中发挥作用。通过连续酶联免疫吸附测定法（ELISA）对34例脓毒症患者的HILDA/LIF和白细胞介素-6（IL-6）水平进行了前瞻性研究。在34例患者中的11例检测到HILDA/LIF，血浆水平为100 - 37,000 pg/mL。HILDA/LIF峰值水平与体温升高、肌酐升高、IL-6升高以及动脉血二氧化碳分压降低相关（P <.05）。多变量分析显示，休克和动脉血二氧化碳分压降低占HILDA/LIF血浆峰值变化的75%（R2 =.753）。死亡结局最常与可检测到的HILDA/LIF（> 56 pg/mL）和IL-6血浆峰值水平> 850 pg/mL相关（敏感性为83%；特异性为87%），但两者（分别在> 480和> 850 pg/mL水平）均与死亡结局相关。在出现休克的脓毒症患者中检测到HILDA/LIF，其水平与更高的死亡率和更短的生存期相关。